When monitoring a patient receiving IV cisplatin, what potential adverse effect should the nurse be most vigilant for?

Cisplatin is a platinum-based chemotherapy agent commonly used to treat various cancers. One of the most significant adverse effects associated with cisplatin is bone marrow suppression. This can lead to a decrease in the production of blood cells, specifically red blood cells, white blood cells, and platelets, resulting in anemia, increased susceptibility to infections, and increased risk of bleeding.

Monitoring for signs of bone marrow suppression is crucial, as these complications can significantly impact the patient's overall health and complicate cancer treatment. Regular blood counts are typically performed to assess the levels of these cells throughout therapy.

While cisplatin can lead to other adverse effects, such as nausea, renal toxicity, ototoxicity, and peripheral neuropathy, the most immediate and significant concern in the context of monitoring during treatment is the risk of bone marrow suppression.